Management of Heavy Menstrual Bleeding After Nexplanon Insertion
First, rule out pregnancy, STDs, and pathologic uterine conditions (polyps, fibroids), then treat with NSAIDs for 5-7 days or combined oral contraceptives for 10-20 days if no contraindications exist; if bleeding persists and is unacceptable, counsel on alternative contraceptive methods. 1
Initial Evaluation
When a patient presents with heavy bleeding 5 months after Nexplanon insertion, you need to exclude:
- Pregnancy (including ectopic pregnancy, which may be more likely in implant users who conceive) 2
- Sexually transmitted infections (chlamydia, gonorrhea)
- New pathologic uterine conditions such as polyps or fibroids
- Drug interactions that might affect bleeding patterns 1
This evaluation is clinically indicated because while bleeding irregularities are common with the etonogestrel implant, heavy or prolonged bleeding is actually uncommon during implant use 1. The FDA label confirms that approximately 18% of users experience prolonged bleeding, but this is not the typical pattern 2.
Treatment Algorithm
If No Underlying Pathology is Found:
First-line options during days of bleeding:
NSAIDs (Mefenamic acid): 500 mg three times daily for 5-7 days 1
- Evidence shows significant bleeding cessation within 7 days compared to placebo 1
- This is the safest option with no hormonal contraindications
Combined oral contraceptives (COCs): Low-dose formulation for 10-20 days 1
- Only if medically eligible (no contraindications to estrogen)
- Recent high-quality evidence from 2020 shows COCs (20 mcg ethinyl estradiol/150 mcg desogestrel) for two continuous cycles resulted in 76.2% of women stopping bleeding within 7 days, significantly better than NSAIDs (35.7%) 3
- A 2015 RCT demonstrated 87.5% of women achieved temporary bleeding interruption with 14-day OCP treatment versus 37.5% with placebo 4
Important Caveats:
- COCs work better but bleeding typically recurs: 85.7% of women who stopped bleeding with OCPs had recurrence within 10 days after treatment cessation 4
- Norethisterone acetate (10 mg daily) is effective for stopping bleeding (86.7% cessation within 7 days) but also has high recurrence rates (median 5 days to recurrence) 5
- Tranexamic acid does NOT work: A 2026 RCT showed no benefit over placebo for implant-related bleeding 6
When to Consider Implant Removal
If irregular bleeding persists after treatment and the woman finds it unacceptable, counsel her on alternative contraceptive methods and offer another method if desired. 1
Key considerations:
- Bleeding patterns in the first 3 months are broadly predictive of future patterns 2
- Changes in bleeding pattern were the most common reason for implant discontinuation (11.1% in clinical trials) 2
- Women with historically irregular menses or those seeking the implant primarily for menstrual management are more likely to report bothersome bleeding 7
Reassurance and Counseling
Emphasize that:
- Bleeding irregularities are generally not harmful 1
- Heavy or prolonged bleeding is uncommon with implant use 1
- The implant remains highly effective contraception despite bleeding changes 2
- Over 50% of recipients with managed bothersome bleeding continue the implant for 3 years 7
Critical Safety Note
Always assess for thrombotic risk factors before prescribing estrogen-containing treatments, as postmarketing reports include serious arterial and venous thromboembolic events (pulmonary emboli, DVT, MI, strokes) in etonogestrel implant users 2. While the causal relationship is unclear, women with VTE risk factors should receive NSAIDs rather than hormonal treatment.